Previous 10 | Next 10 |
-- Analysis of 20 African Americans from the pivotal study presented at the 15th World Congress on Controversies in Neurology -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced results of a retrospective analysis of the pivotal Phase 2/3 N-MOmentum clinical trial, in...
-- Genetic counselor algorithms identify at-risk patients to help shorten the rare, genetic disease odyssey -- -- Next - generation sequencing data delivers personalized rare disease therapies in an equitable manner to underrepresented communities -- Ho...
HemoShear Therapeutics Advancing Several Novel Compounds for Horizon Therapeutics plc Gout Discovery Pipeline - Milestone Achieved by HemoShear in Exclusive Drug Discovery Collaboration - PR Newswire CHARLOTTESVILLE, Va. , Sept. 21, 2021 /PRNewswire/ --...
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named to the 2021 Best Workplaces for Women™ list for the first time by Fortune and Great Place to Work ® . The Best Workplaces for Women award spotlights the top U.S. companies who have made a ...
John Paulson’s 13F portfolio value remained steady at $4.35B this quarter. Paulson & Company's added DiDi Global & increased Occidental Petroleum while reducing Viatris and dropping Takeda. The top three positions are at 45% of the portfolio. For further detai...
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the first patient has been enrolled in a Phase 4 clinical trial evaluating the efficacy and safety of TEPEZZA for the treatment of chronic (inactive) TED. TEPEZZA is the first and only medicine approved by the U.S. Food and Dr...
Shares of Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) traded today at $111.64, eclipsing its 52-week high. Approximately 128,000 shares have changed hands today, as compared to an average 30-day volume of 1.2 million shares. Horizon Therapeutics Public Limited Company share...
My portfolio, built specifically for my retirement ~20+ years from now, eclipses new highs as the market continues to grind higher. Making monthly contributions, even though they seem small at the time, makes all the difference in the world over time in helping create a valuable retir...
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named to PEOPLE's 100 Companies That Care ® 2021 list for the third year by PEOPLE and Great Place to Work ® . The PEOPLE Companies that Care list spotlights the top U.S. companies who have su...
Acer Therapeutics is a pharmaceutical company that acquires, develops and seeks to commercialize therapies for serious, rare, and life-threatening diseases. Acer submitted an NDA for its lead drug candidate ACER-001 for treatment of UCDs in early August. Acer expects notification ...
News, Short Squeeze, Breakout and More Instantly...
Horizon Therapeutics Public Limited Company Company Name:
HZNP Stock Symbol:
NASDAQ Market:
Horizon Therapeutics Public Limited Company Website:
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
Horizon Therapeutics Public Limited Company (HZNP) is expected to report $1.22 for Q3 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE October 6, 2023 RECOM...